Compare McKesson Corporation (MCK) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs McCormick & Company, Incorporated — how do they compare? McKesson Corporation trades at $937.85 (market cap $108.46B), while McCormick & Company, Incorporated trades at $46 (market cap $12.39B). The key difference: McKesson Corporation is far larger — about 8.8× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and McCormick & Company, Incorporated for 67 Days on average.
| MCK | MKC | |
|---|---|---|
Market Cap | $108.46B | $12.39B |
Volume | 712,607 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $995.69 | $71.65 |
52-Week Low | $725.17 | $44.14 |
Typical Hold Time | 74 Days | 67 Days |
Enterprise Value | $115.00B | $17.07B |
Dividend Yield | 0.4% | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
McCormick & Company (MKC) trades at $45.25, down 0.33% with a bearish technical signal despite strong Q3 2026 earnings that beat estimates. The stock shows attractive valuation metrics with a P/E of 8.18 and robust profitability including 19.39% net income margin. Recent performance reflects 17% sales growth driven by the Mexico acquisition and margin expansion, though technical indicators suggest near-term pressure with support at $44.
MKC presents a compelling value opportunity with below-sector P/E ratio and consistent dividend payments, though bearish technicals and mixed analyst sentiment (33% buy, 60% hold) indicate caution. Upside potential exists to the $53.50 consensus target, but investors face risks from integration challenges and macroeconomic pressure on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
